Loading...

Trever Bivona, MD, PhD

TitleAssociate Professor
SchoolUCSF School of Medicine
DepartmentMedicine
Address600 16th St
San Francisco CA 94158
Phone415-476-9907
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    New York UniversityM.D.2005School of Medicine

    Collapse Research 
    Collapse Research Activities and Funding
    Bay Area Team Against Resistance
    NIH/NCI U54CA224081Sep 30, 2017 - Aug 31, 2019
    Role: Principal Investigator
    The Cancer Target Discovery and Development Network at UCSF
    NIH/NCI U01CA217882Aug 10, 2017 - Jul 31, 2022
    Role: Co-Principal Investigator
    Characterization of YAP as a rational companion target in lung cancer
    NIH/NCI R01CA204302Mar 1, 2017 - Feb 28, 2022
    Role: Principal Investigator
    Optimizing biologically-based rational polytherapy in ALK+ lung cancer
    NIH/NCI R01CA211052Jan 11, 2017 - Dec 31, 2021
    Role: Principal Investigator
    Rational Combined Inhibition of NF-kB and EGFR to Optimize Lung Cancer Treatment
    NIH/NCI R01CA169338Feb 1, 2013 - Jan 31, 2018
    Role: Principal Investigator
    Discovery of Rational Companion Therapeutic Targets to Optimize Cancer Treatment
    NIH/NCI DP2CA174497Sep 15, 2012 - Aug 31, 2017
    Role: Principal Investigator
    Genetic Modifiers such as Fas Regulate Tumor-Cell Dependence on Mutant EGFR
    NIH/NCI K08CA154787Sep 21, 2011 - Aug 31, 2016
    Role: Principal Investigator

    Collapse ORNG Applications 
    Collapse Websites
    Collapse In The News
    Collapse Global Health
    Collapse Student Projects

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Chaib I, Karachaliou N, Pilotto S, Codony Servat J, Cai X, Li X, Drozdowskyj A, Servat CC, Yang J, Hu C, Cardona AF, Vivanco GL, Vergnenegre A, Sanchez JM, Provencio M, de Marinis F, Passaro A, Carcereny E, Reguart N, Campelo CG, Teixido C, Sperduti I, Rodriguez S, Lazzari C, Verlicchi A, de Aguirre I, Queralt C, Wei J, Estrada R, Puig de la Bellacasa R, Ramirez JL, Jacobson K, Ditzel HJ, Santarpia M, Viteri S, Molina MA, Zhou C, Cao P, Ma PC, Bivona T, Rosell R. Co-activation of STAT3 and YES-Associated Protein 1 (YAP1) Pathway in EGFR-Mutant NSCLC. J Natl Cancer Inst. 2017 09 01; 109(9). PMID: 28376152.
      View in: PubMed
    2. Mayekar MK, Bivona T. Current Landscape of Targeted Therapy in Lung Cancer. Clin Pharmacol Ther. 2017 Aug 08. PMID: 28786099.
      View in: PubMed
    3. Codony-Servat C, Codony-Servat J, Karachaliou N, Molina MA, Chaib I, Ramirez JL, de Los Llanos Gil M, Solca F, Bivona T, Rosell R. Activation of signal transducer and activator of transcription 3 (STAT3) signaling in EGFR mutant non-small-cell lung cancer (NSCLC). Oncotarget. 2017 Jul 18; 8(29):47305-47316. PMID: 28521301.
      View in: PubMed
    4. Wang VE, Young L, Ali S, Miller VA, Urisman A, Wolfe J, Bivona T, Damato B, Fogh S, Bergsland EK. A Case of Metastatic Atypical Neuroendocrine Tumor with ALK Translocation and Diffuse Brain Metastases. Oncologist. 2017 Jul; 22(7):768-773. PMID: 28507205.
      View in: PubMed
    5. Jonsson VD, Blakely CM, Lin L, Asthana S, Matni N, Olivas V, Pazarentzos E, Gubens MA, Bastian BC, Taylor BS, Doyle JC, Bivona T. Novel computational method for predicting polytherapy switching strategies to overcome tumor heterogeneity and evolution. Sci Rep. 2017 Mar 13; 7:44206. PMID: 28287179.
      View in: PubMed
    6. Wang V, Bivona T, Ali SM, Schrock AB, Miller VA. CD74-ROS1 Fusion in NSCLC Detected by Hybrid Capture-Based Tissue Genomic Profiling and ctDNA Assays. J Thorac Oncol. 2017 Feb; 12(2):e19-e20. PMID: 28115114.
      View in: PubMed
    7. Kyung Rho J, Young Lee I, Jung Choi Y, Choi CM, Hur JY, Koh JS, Lee J, Suh BC, Song HJ, Salgaonkar P, Lee J, Lee J, Jung DS, Kim SY, Woo DC, Baek IJ, Lee JY, Ha CH, Sung YH, Kim JK, Kim WS, Song JS, Kim CH, Bivona T, Lee JC. Superior Efficacy and Selectivity of Novel Small-Molecule Kinase Inhibitors of T790M-Mutant EGFR in Preclinical Models of Lung Cancer. Cancer Res. 2017 Mar 01; 77(5):1200-1211. PMID: 28082405.
      View in: PubMed
    8. Okimoto RA, Bivona T. Metastasis: From head to tail. Cell Cycle. 2017 Mar 19; 16(6):487-488. PMID: 28055306.
      View in: PubMed
    9. Thiagarajan PS, Wu X, Zhang W, Shi I, Bagai R, Leahy P, Feng Y, Veigl M, Lindner D, Danielpour D, Yin L, Rosell R, Bivona T, Zhang Z, Ma PC. Transcriptomic-metabolomic reprogramming in EGFR-mutant NSCLC early adaptive drug escape linking TGFß2-bioenergetics-mitochondrial priming. Oncotarget. 2016 Dec 13; 7(50):82013-82027. PMID: 27852038.
      View in: PubMed
    10. Okimoto RA, Breitenbuecher F, Olivas VR, Wu W, Gini B, Hofree M, Asthana S, Hrustanovic G, Flanagan J, Tulpule A, Blakely CM, Haringsma HJ, Simmons AD, Gowen K, Suh J, Miller VA, Ali S, Schuler M, Bivona T. Inactivation of Capicua drives cancer metastasis. Nat Genet. 2017 Jan; 49(1):87-96. PMID: 27869830.
      View in: PubMed
    11. Okimoto RA, Lin L, Olivas V, Chan E, Markegard E, Rymar A, Neel D, Chen X, Hemmati G, Bollag G, Bivona T. Preclinical efficacy of a RAF inhibitor that evades paradoxical MAPK pathway activation in protein kinase BRAF-mutant lung cancer. Proc Natl Acad Sci U S A. 2016 Nov 22; 113(47):13456-13461. PMID: 27834212.
      View in: PubMed
    12. Sabnis AJ, Bivona T. HSP70 dependence in rhabdomyosarcoma: Seed or soil? Cell Cycle. 2017 Jan 17; 16(2):147-148. PMID: 27686974.
      View in: PubMed
    13. Sabnis AJ, Guerriero CJ, Olivas V, Sayana A, Shue J, Flanagan J, Asthana S, Paton AW, Paton JC, Gestwicki JE, Walter P, Weissman JS, Wipf P, Brodsky JL, Bivona T. Combined chemical-genetic approach identifies cytosolic HSP70 dependence in rhabdomyosarcoma. Proc Natl Acad Sci U S A. 2016 Aug 09; 113(32):9015-20. PMID: 27450084; PMCID: PMC4987817 [Available on 02/09/17].
    14. Premasekharan G, Gilbert E, Okimoto RA, Hamirani A, Lindquist KJ, Ngo VT, Roy R, Hough J, Edwards M, Paz R, Foye A, Sood R, Copren KA, Gubens M, Small EJ, Bivona T, Collisson EA, Friedlander TW, Paris PL. An improved CTC isolation scheme for pairing with downstream genomics: Demonstrating clinical utility in metastatic prostate, lung and pancreatic cancer. Cancer Lett. 2016 Sep 28; 380(1):144-52. PMID: 27343980.
      View in: PubMed
    15. McCoach CE, Bivona T, Blakely CM, Doebele RC. Neoadjuvant Oncogene-Targeted Therapy in Early Stage Non-Small-Cell Lung Cancer as a Strategy to Improve Clinical Outcome and Identify Early Mechanisms of Resistance. Clin Lung Cancer. 2016 Sep; 17(5):466-469. PMID: 27378174.
      View in: PubMed
    16. Bivona T, Doebele RC. A framework for understanding and targeting residual disease in oncogene-driven solid cancers. Nat Med. 2016 May 05; 22(5):472-8. PMID: 27149220.
      View in: PubMed
    17. Hrustanovic G, Bivona T. RAS signaling in ALK fusion lung cancer. Small GTPases. 2016; 7(1):32-3. PMID: 26901483; PMCID: PMC4905280 [Available on 02/22/17].
    18. Okimoto RA, Bivona T. Tracking Down Response and Resistance to TRK Inhibitors. Cancer Discov. 2016 Jan; 6(1):14-6. PMID: 26747892; PMCID: PMC4709026.
    19. Hrustanovic G, Bivona T. RAS-MAPK signaling influences the efficacy of ALK-targeting agents in lung cancer. Mol Cell Oncol. 2016 Mar; 3(2):e1091061. PMID: 27308613; PMCID: PMC4905399 [Available on 10/29/16].
    20. Hrustanovic G, Olivas V, Pazarentzos E, Tulpule A, Asthana S, Blakely CM, Okimoto RA, Lin L, Neel DS, Sabnis A, Flanagan J, Chan E, Varella-Garcia M, Aisner DL, Vaishnavi A, Ou SH, Collisson EA, Ichihara E, Mack PC, Lovly CM, Karachaliou N, Rosell R, Riess JW, Doebele RC, Bivona T. RAS-MAPK dependence underlies a rational polytherapy strategy in EML4-ALK-positive lung cancer. Nat Med. 2015 Sep; 21(9):1038-47. PMID: 26301689; PMCID: PMC4734742.
    21. Zill OA, Greene C, Sebisanovic D, Siew LM, Leng J, Vu M, Hendifar AE, Wang Z, Atreya CE, Kelley RK, Van Loon K, Ko AH, Tempero MA, Bivona T, Munster PN, Talasaz A, Collisson EA. Cell-Free DNA Next-Generation Sequencing in Pancreatobiliary Carcinomas. Cancer Discov. 2015 Oct; 5(10):1040-8. PMID: 26109333; PMCID: PMC4592417.
    22. Pazarentzos E, Giannikopoulos P, Hrustanovic G, St John J, Olivas VR, Gubens MA, Balassanian R, Weissman J, Polkinghorn W, Bivona T. Oncogenic activation of the PI3-kinase p110ß isoform via the tumor-derived PIK3Cß(D1067V) kinase domain mutation. Oncogene. 2016 Mar 03; 35(9):1198-205. PMID: 25982275.
      View in: PubMed
    23. Okimoto RA, Bivona T. AXL receptor tyrosine kinase as a therapeutic target in NSCLC. Lung Cancer (Auckl). 2015; 6:27-34. PMID: 28210148.
      View in: PubMed
    24. Lin L, Bivona T. The Hippo effector YAP regulates the response of cancer cells to MAPK pathway inhibitors. Mol Cell Oncol. 2016 Jan; 3(1):e1021441. PMID: 27308535; PMCID: PMC4845171.
    25. Elkabets M, Pazarentzos E, Juric D, Sheng Q, Pelossof RA, Brook S, Benzaken AO, Rodon J, Morse N, Yan JJ, Liu M, Das R, Chen Y, Tam A, Wang H, Liang J, Gurski JM, Kerr DA, Rosell R, Teixidó C, Huang A, Ghossein RA, Rosen N, Bivona T, Scaltriti M, Baselga J. AXL mediates resistance to PI3Ka inhibition by activating the EGFR/PKC/mTOR axis in head and neck and esophageal squamous cell carcinomas. Cancer Cell. 2015 Apr 13; 27(4):533-46. PMID: 25873175; PMCID: PMC4398915.
    26. Blakely CM, Pazarentzos E, Olivas V, Asthana S, Yan JJ, Tan I, Hrustanovic G, Chan E, Lin L, Neel DS, Newton W, Bobb KL, Fouts TR, Meshulam J, Gubens MA, Jablons DM, Johnson JR, Bandyopadhyay S, Krogan NJ, Bivona T. NF-?B-activating complex engaged in response to EGFR oncogene inhibition drives tumor cell survival and residual disease in lung cancer. Cell Rep. 2015 Apr 07; 11(1):98-110. PMID: 25843712; PMCID: PMC4394036.
    27. Choi YJ, Kim SY, So KS, Baek IJ, Kim WS, Choi SH, Lee JC, Bivona T, Rho JK, Choi CM. AUY922 effectively overcomes MET- and AXL-mediated resistance to EGFR-TKI in lung cancer cells. PLoS One. 2015; 10(3):e0119832. PMID: 25780909; PMCID: PMC4363657.
    28. Pazarentzos E, Bivona T. Adaptive stress signaling in targeted cancer therapy resistance. Oncogene. 2015 Nov 05; 34(45):5599-606. PMID: 25703329; PMCID: PMC4546915.
    29. Lin L, Sabnis AJ, Chan E, Olivas V, Cade L, Pazarentzos E, Asthana S, Neel D, Yan JJ, Lu X, Pham L, Wang MM, Karachaliou N, Cao MG, Manzano JL, Ramirez JL, Torres JM, Buttitta F, Rudin CM, Collisson EA, Algazi A, Robinson E, Osman I, Muñoz-Couselo E, Cortes J, Frederick DT, Cooper ZA, McMahon M, Marchetti A, Rosell R, Flaherty KT, Wargo JA, Bivona T. The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies. Nat Genet. 2015 Mar; 47(3):250-6. PMID: 25665005; PMCID: PMC4930244.
    30. Flaherty KT, Wargo JA, Bivona T. YAP in MAPK pathway targeted therapy resistance. Cell Cycle. 2015; 14(12):1765-6. PMID: 26036142; PMCID: PMC4612653.
    31. Hrustanovic G, Bivona T. RAS-MAPK in ALK targeted therapy resistance. Cell Cycle. 2015; 14(23):3661-2. PMID: 26654768; PMCID: PMC4825705 [Available on 12/11/16].
    32. Shen J, Wei J, Guan W, Wang H, Ding Y, Qian X, Yu L, Zou Z, Xie L, Costa C, Bivona T, Rosell R, Liu B. Plasma mRNA expression levels of BRCA1 and TS as potential predictive biomarkers for chemotherapy in gastric cancer. J Transl Med. 2014 Dec 14; 12:355. PMID: 25496700; PMCID: PMC4302091.
    33. Rolfo C, Giovannetti E, Hong DS, Bivona T, Raez LE, Bronte G, Buffoni L, Reguart N, Santos ES, Germonpre P, Taron M, Passiglia F, Van Meerbeeck JP, Russo A, Peeters M, Gil-Bazo I, Pauwels P, Rosell R. Novel therapeutic strategies for patients with NSCLC that do not respond to treatment with EGFR inhibitors. Cancer Treat Rev. 2014 Sep; 40(8):990-1004. PMID: 24953979.
      View in: PubMed
    34. Costa C, Molina MA, Drozdowskyj A, Giménez-Capitán A, Bertran-Alamillo J, Karachaliou N, Gervais R, Massuti B, Wei J, Moran T, Majem M, Felip E, Carcereny E, Garcia-Campelo R, Viteri S, Taron M, Ono M, Giannikopoulos P, Bivona T, Rosell R. The impact of EGFR T790M mutations and BIM mRNA expression on outcome in patients with EGFR-mutant NSCLC treated with erlotinib or chemotherapy in the randomized phase III EURTAC trial. Clin Cancer Res. 2014 Apr 01; 20(7):2001-10. PMID: 24493829.
      View in: PubMed
    35. Lin L, Asthana S, Chan E, Bandyopadhyay S, Martins MM, Olivas V, Yan JJ, Pham L, Wang MM, Bollag G, Solit DB, Collisson EA, Rudin CM, Taylor BS, Bivona T. Mapping the molecular determinants of BRAF oncogene dependence in human lung cancer. Proc Natl Acad Sci U S A. 2014 Feb 18; 111(7):E748-57. PMID: 24550319; PMCID: PMC3932924.
    36. Molina-Vila MA, Nabau-Moretó N, Tornador C, Sabnis AJ, Rosell R, Estivill X, Bivona T, Marino-Buslje C. Activating mutations cluster in the "molecular brake" regions of protein kinases and do not associate with conserved or catalytic residues. Hum Mutat. 2014 Mar; 35(3):318-28. PMID: 24323975.
      View in: PubMed
    37. Okimoto RA, Bivona T. Recent advances in personalized lung cancer medicine. Per Med. 2014; 11(3):309-321. PMID: 25506379.
      View in: PubMed
    38. Rosell R, Bivona T, Karachaliou N. Genetics and biomarkers in personalisation of lung cancer treatment. Lancet. 2013 Aug 24; 382(9893):720-31. PMID: 23972815.
      View in: PubMed
    39. Sabnis AJ, Bivona T. FGFR fusions in the driver's seat. Cancer Discov. 2013 Jun; 3(6):607-9. PMID: 23749526; PMCID: PMC4988530.
    40. Hrustanovic G, Lee BJ, Bivona T. Mechanisms of resistance to EGFR targeted therapies. Cancer Biol Ther. 2013 Apr; 14(4):304-14. PMID: 23358468; PMCID: PMC3667869.
    41. Neel DS, Bivona T. Secrets of drug resistance in NSCLC exposed by new molecular definition of EMT. Clin Cancer Res. 2013 Jan 01; 19(1):3-5. PMID: 23172883; PMCID: PMC3537879.
    42. Blakely CM, Bivona T. Resiliency of lung cancers to EGFR inhibitor treatment unveiled, offering opportunities to divide and conquer EGFR inhibitor resistance. Cancer Discov. 2012 Oct; 2(10):872-5. PMID: 23071030; PMCID: PMC3475614.
    43. Lin L, Bivona T. Mechanisms of Resistance to Epidermal Growth Factor Receptor Inhibitors and Novel Therapeutic Strategies to Overcome Resistance in NSCLC Patients. Chemother Res Pract. 2012; 2012:817297. PMID: 22970367; PMCID: PMC3437267.
    44. Zhang Z, Lee JC, Lin L, Olivas V, Au V, LaFramboise T, Abdel-Rahman M, Wang X, Levine AD, Rho JK, Choi YJ, Choi CM, Kim SW, Jang SJ, Park YS, Kim WS, Lee DH, Lee JS, Miller VA, Arcila M, Ladanyi M, Moonsamy P, Sawyers C, Boggon TJ, Ma PC, Costa C, Taron M, Rosell R, Halmos B, Bivona T. Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer. Nat Genet. 2012 Jul 01; 44(8):852-60. PMID: 22751098; PMCID: PMC3408577.
    45. Morris LG, Taylor BS, Bivona T, Gong Y, Eng S, Brennan CW, Kaufman A, Kastenhuber ER, Banuchi VE, Singh B, Heguy A, Viale A, Mellinghoff IK, Huse J, Ganly I, Chan TA. Genomic dissection of the epidermal growth factor receptor (EGFR)/PI3K pathway reveals frequent deletion of the EGFR phosphatase PTPRS in head and neck cancers. Proc Natl Acad Sci U S A. 2011 Nov 22; 108(47):19024-9. PMID: 22065749; PMCID: PMC3223475.
    46. Bivona T, Hieronymus H, Parker J, Chang K, Taron M, Rosell R, Moonsamy P, Dahlman K, Miller VA, Costa C, Hannon G, Sawyers CL. FAS and NF-?B signalling modulate dependence of lung cancers on mutant EGFR. Nature. 2011 Mar 24; 471(7339):523-6. PMID: 21430781; PMCID: PMC3541675.
    47. Rosell R, Molina MA, Costa C, Simonetti S, Gimenez-Capitan A, Bertran-Alamillo J, Mayo C, Moran T, Mendez P, Cardenal F, Isla D, Provencio M, Cobo M, Insa A, Garcia-Campelo R, Reguart N, Majem M, Viteri S, Carcereny E, Porta R, Massuti B, Queralt C, de Aguirre I, Sanchez JM, Sanchez-Ronco M, Mate JL, Ariza A, Benlloch S, Sanchez JJ, Bivona T, Sawyers CL, Taron M. Pretreatment EGFR T790M mutation and BRCA1 mRNA expression in erlotinib-treated advanced non-small-cell lung cancer patients with EGFR mutations. Clin Cancer Res. 2011 Mar 01; 17(5):1160-8. PMID: 21233402.
      View in: PubMed
    48. Quatela SE, Sung PJ, Ahearn IM, Bivona T, Philips MR. Analysis of K-Ras phosphorylation, translocation, and induction of apoptosis. Methods Enzymol. 2008; 439:87-102. PMID: 18374158.
      View in: PubMed
    49. Bivona T, Quatela SE, Bodemann BO, Ahearn IM, Soskis MJ, Mor A, Miura J, Wiener HH, Wright L, Saba SG, Yim D, Fein A, Pérez de Castro I, Li C, Thompson CB, Cox AD, Philips MR. PKC regulates a farnesyl-electrostatic switch on K-Ras that promotes its association with Bcl-XL on mitochondria and induces apoptosis. Mol Cell. 2006 Feb 17; 21(4):481-93. PMID: 16483930.
      View in: PubMed
    50. Bivona T, Quatela S, Philips MR. Analysis of Ras activation in living cells with GFP-RBD. Methods Enzymol. 2006; 407:128-43. PMID: 16757320.
      View in: PubMed
    51. Bivona T, Philips MR. Analysis of Ras and Rap activation in living cells using fluorescent Ras binding domains. Methods. 2005 Oct; 37(2):138-45. PMID: 16289969.
      View in: PubMed
    52. Jordan JD, He JC, Eungdamrong NJ, Gomes I, Ali W, Nguyen T, Bivona T, Philips MR, Devi LA, Iyengar R. Cannabinoid receptor-induced neurite outgrowth is mediated by Rap1 activation through G(alpha)o/i-triggered proteasomal degradation of Rap1GAPII. J Biol Chem. 2005 Mar 25; 280(12):11413-21. PMID: 15657046.
      View in: PubMed
    53. Dustin ML, Bivona T, Philips MR. Membranes as messengers in T cell adhesion signaling. Nat Immunol. 2004 Apr; 5(4):363-72. PMID: 15052266.
      View in: PubMed
    54. Perez de Castro I, Bivona T, Philips MR, Pellicer A. Ras activation in Jurkat T cells following low-grade stimulation of the T-cell receptor is specific to N-Ras and occurs only on the Golgi apparatus. Mol Cell Biol. 2004 Apr; 24(8):3485-96. PMID: 15060167; PMCID: PMC381594.
    55. Walker SA, Kupzig S, Bouyoucef D, Davies LC, Tsuboi T, Bivona T, Cozier GE, Lockyer PJ, Buckler A, Rutter GA, Allen MJ, Philips MR, Cullen PJ. Identification of a Ras GTPase-activating protein regulated by receptor-mediated Ca2+ oscillations. EMBO J. 2004 Apr 21; 23(8):1749-60. PMID: 15057271; PMCID: PMC394250.
    56. Zhang SQ, Yang W, Kontaridis MI, Bivona T, Wen G, Araki T, Luo J, Thompson JA, Schraven BL, Philips MR, Neel BG. Shp2 regulates SRC family kinase activity and Ras/Erk activation by controlling Csk recruitment. Mol Cell. 2004 Feb 13; 13(3):341-55. PMID: 14967142.
      View in: PubMed
    57. Bivona T, Wiener HH, Ahearn IM, Silletti J, Chiu VK, Philips MR. Rap1 up-regulation and activation on plasma membrane regulates T cell adhesion. J Cell Biol. 2004 Feb 02; 164(3):461-70. PMID: 14757755; PMCID: PMC2172240.
    58. Mohney RP, Das M, Bivona T, Hanes R, Adams AG, Philips MR, O'Bryan JP. Intersectin activates Ras but stimulates transcription through an independent pathway involving JNK. J Biol Chem. 2003 Nov 21; 278(47):47038-45. PMID: 12970366.
      View in: PubMed
    59. Bivona T, Pérez De Castro I, Ahearn IM, Grana TM, Chiu VK, Lockyer PJ, Cullen PJ, Pellicer A, Cox AD, Philips MR. Phospholipase Cgamma activates Ras on the Golgi apparatus by means of RasGRP1. Nature. 2003 Aug 07; 424(6949):694-8. PMID: 12845332.
      View in: PubMed
    60. Bivona T, Philips MR. Ras pathway signaling on endomembranes. Curr Opin Cell Biol. 2003 Apr; 15(2):136-42. PMID: 12648668.
      View in: PubMed
    61. Chiu VK, Bivona T, Hach A, Sajous JB, Silletti J, Wiener H, Johnson RL, Cox AD, Philips MR. Ras signalling on the endoplasmic reticulum and the Golgi. Nat Cell Biol. 2002 May; 4(5):343-50. PMID: 11988737.
      View in: PubMed
    62. Robibaro B, Stedman TT, Coppens I, Ngô HM, Pypaert M, Bivona T, Nam HW, Joiner KA. Toxoplasma gondii Rab5 enhances cholesterol acquisition from host cells. Cell Microbiol. 2002 Mar; 4(3):139-52. PMID: 11906451.
      View in: PubMed
    Trever's Networks
    Concepts
    Derived automatically from this person's publications.
    _
    Co-Authors
    People in Profiles who have published with this person.
    _
    Related Authors
    People who share related concepts with this person.
    _
    Back to TOP